prikaz prve stranice dokumenta TIGIT therapy for cancer treatment – TIGITtherapy – ERC
  Download
PDF 412.83 KB
Other - Popular paper
TIGIT therapy for cancer treatment – TIGITtherapy – ERC
Impact, 2018 (2018), 10; 51-53. https://doi.org/10.21820/23987073.2018.10.51
Mandelboim, Ofer; Jonjić, Stipan; Kučan Brlić, Paola; Tsukerman, Pinchas

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Mandelboim, O., Jonjić, S., Kučan Brlić, P. & Tsukerman, P. (2018). TIGIT therapy for cancer treatment – TIGITtherapy – ERC. Impact, 2018. (10), 51-53. doi: 10.21820/23987073.2018.10.51

Mandelboim, Ofer, et al. "TIGIT therapy for cancer treatment – TIGITtherapy – ERC." Impact, vol. 2018, no. 10, 2018, pp. 51-53. https://doi.org/10.21820/23987073.2018.10.51

Mandelboim, Ofer, Stipan Jonjić, Paola Kučan Brlić and Pinchas Tsukerman. "TIGIT therapy for cancer treatment – TIGITtherapy – ERC." Impact 2018, no. 10 (2018): 51-53. https://doi.org/10.21820/23987073.2018.10.51

Mandelboim, O., et al. (2018) 'TIGIT therapy for cancer treatment – TIGITtherapy – ERC', Impact, 2018(10), pp. 51-53. doi: 10.21820/23987073.2018.10.51

Mandelboim O, Jonjić S, Kučan Brlić P, Tsukerman P. TIGIT therapy for cancer treatment – TIGITtherapy – ERC. Impact [Internet]. 2018 December 21 [cited 2024 May 14];2018(10):51-53. doi: 10.21820/23987073.2018.10.51

O. Mandelboim, S. Jonjić, P. Kučan Brlić and P. Tsukerman, "TIGIT therapy for cancer treatment – TIGITtherapy – ERC", Impact, vol. 2018, no. 10, pp. 51-53, December 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:389585. [Accessed: 14 May 2024]

Metadata
Title (english)TIGIT therapy for cancer treatment – TIGITtherapy – ERC
AuthorOfer Mandelboim
AuthorStipan Jonjić
AuthorPaola Kučan Brlić
AuthorPinchas Tsukerman
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Center for Proteomics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Treating tumors with immune-related therapies is one of the most exciting and promising advancements made in the past decade. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market. TIGIT is an important checkpoint inhibitory receptor discovered by our group in 2009. It is constitutively expressed by various immune cells and its expression is further increased on tumor infiltrating lymphocytes (TILs). TIGIT recognizes two main ligands, PVR and Nectin2 that are highly expressed on various tumors. Blockage of TIGIT on TILs either alone or in combination with another checkpoint inhibitory receptor, PD-1, leads to increased T and Natural Killer (NK) cell activity in vitro and inhibited tumor growth in vivo. We developed highly specific blocking antibodies, that block TIGIT at pM affinity and restore effector function of NK and T cells.
Keywords (english)
Languageenglish
Publication typeOther - Popular paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleImpact
Numberingvol. 2018, no. 10, pp. 51-53
p-ISSN2398-7073
DOIhttps://doi.org/10.21820/23987073.2018.10.51
URN:NBNurn:nbn:hr:184:389585
Publication2018-12-21
ProjectNumber: 721317
Title (english): TIGIT therapy for cancer treatment
Acronym: TIGITtherapy
Jurisdiction: eu
Funding stream: H2020
Document URLhttps://www.ingentaconnect.com/content/10.21820/23987073.2018.10.51
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-10-19 07:52:32